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Apparent Diffusion Coefficient (ADC)Objective: Evaluate the role of Diffusion Weighted (DW-MRI) and Dynamic contrast
enhanced Magnetic Resonance Imaging (DCE-MRI) in assessment of recurrent/residual
malignant liver tumors after percutaneous radiofrequency ablation.
Patients and methods: This study included 50 patients, 40 males and 10 females. Patients
ages ranged from 45 to 80 years with the mean age of 60 years. Patients were referred from
Tropical Department for MRI unit after the radiofrequency ablation for malignant liver
tumors for assessment of recurrent/residual liver tumors.
Results: Thirty-seven patients (74%) had resolved lesions while 13 patients (26%) had
recurrent/residual lesions. The border of resolved lesions was smooth but in unresolved
lesions was nodular in 11 patients out of 13 (84.6%) and irregular in two patients
(15.4%). The measured cut off value between the completely ablated lesions and resid-
ual/recurrent lesions was 1.05  103 mm2/s. The ablated zones can be differentiated from
liver parenchyma visually in the DWIs and by means of ADC in all patients. There is no sta-
tistical difference in the mean ADC values between the ablated zones of the resolved and
unresolved lesions.
Conclusion: DW-MRI and DCE-MRI show viable tumor regions and suspected areas in the
periphery of the ablated zone could be identified more easily, and analyzed precisely in
conjunction with the conventional MRI.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Liver resection and loco-regional therapies which com-
prise tissue ablation and chemoembolization techniques
are utilized for management of hepatic malignancies [1].
Ablative therapies could be classified into either chemical
or thermal ablation. Chemical ablation includes the useof acetic acid and ethanol, while thermal ablation is gained
by utilizing cold (cryoablation) or heat (radiofrequency
ablation, laser ablation, and microwave ablation). RF abla-
tion is the most widely used for both primary and sec-
ondary hepatic malignances, but all therapies produce
coagulation necrosis, and exhibit common imaging charac-
ters on follow-up. In fact, ablative techniques are a sub-
stantial choice for individuals with hepatic tumors who
are not fit for surgery. These procedures are known to have
low mortality and morbidity, as well as being with lower
cost than surgical resection with the possibility to use
these techniques on outpatient basis [2]. The percutaneous
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preserving the normal liver parenchyma; with low risk of
complication accompanied with the technique and being
easily available and relatively inexpensive, moreover, the
eligibility to easily repeat the procedure in case of recur-
rent lesions [3]. Evaluation of tumor response after loco-
regional treatment is crucial to assess treatment success
and to guide future therapy [4]. After RFA, the dynamic
contrast enhanced MRI for evaluation of the response of
the tumor is still difficult. Residual contrast enhancement
may also be hard to appreciate; hence, some types of sec-
ondary tumors are hypovascular [5]. The MRI characters of
the ablated zones should be assessed for lesion size after
ablation, the signal intensity on unenhanced images, the
presence of perilesional enhancement, and for lesion wash-
out. Moreover, focal liver lesions managed by RFA often
contain a high signal on T1WIs, corresponding to coagula-
tion necrosis, which makes any residual tumor contrast
enhancement difficult to be differentiated [6]. DWI, a tech-
nique, has been helpful in liver tumor detection, tumor
characterization, and monitoring response to treatment
[7–9]. ADC value and DWI parameter, has been correlated
the presence of necrosis and tumor cell necrosis after suc-
cessful treatment [10,11]. Studies have demonstrated a
potential to characterize malignant lesions and to differen-
tiate viable tissue from necrosis on the basis of ADC cutoff
values, because necrosis has higher ADC values [12,13].
The European Association for the Study of Liver Disease
(EASL) has recommended the use of lesion enhancement,
rather than change in size, as the standard method to
determine treatment response. However, uniform rim
enhancement may also result from post-treatment reactive
granulation tissue. Hence, a marker that would assess cel-
lularity, such as DWI, may offer additional benefit to accu-
rately assess tumor necrosis [14]. DWI in the liver in
addition to conventional unenhanced and contrast
enhanced MRI always be used in the follow-up after RFA
shows promising results in the detection of ablation site
recurrence/residual lesions. [15]. ADC was used to assess
metabolic tumor response after loco-regional treatment.
Additionally, some authors have tried to determine
whether the intra-lesion measurement of the lowest ADC
might be helpful in monitoring tumor recurrence, because
this value could reflect the persistence of viable and resid-
ual tumor cells [16].
The aim of the study was to assess the role of (DW-MRI)
and (DCE-MRI) in recurrent/residual malignant liver
tumors after percutaneous radiofrequency ablation and
to improve the technique and to standardize MR protocol
to be used after interventional therapy for malignant liver
tumors.2. Patients and methods
This prospective study was performed in the period
between January 2014 to January 2016. The study included
50 patients, 40 males and 10 females. Their ages ranged
between 45 and 80 years with the mean age of 60 years.
Patients were referred from Tropical Department as wellas from outpatient clinic after the procedure radiofre-
quency ablation.
Inclusion criteria: patients with liver malignancy (HCC
or metastases) after radiofrequency ablation.
Exclusion criteria: contraindications to MRI, con-
traindications to contrast media and liver tumors other
than HCC or metastases.
All patients were subjected to the following:
A. History and clinical examinations
B. Laboratory investigations:1- CBC, HBSAg and HCV.
2- Liver and renal function tests.
3- Tumor markers: Alpha Fetoprotein and Carcino
Embryonic Antigen.
C. RF ablation system:
Radiofrequency ablations were performed for liver
tumors <5 cm, under real time ultrasound guidance using
5 or 3.5 MHz curvilinear probe. Patients were treated
under conscious sedation. The RITA model 1500 RF abla-
tion system provides multiple temperature displays and a
simple intuitive panel design. Radiofrequency energy was
applied from 12 to 15 min; to ensure predictable control-
lable ablations the generator also provides automatic tem-
perature control and impending monitoring. Its needle is
15G, 13–25 cm long insulated cannula that houses 7 solid
expandable curved electrodes. This system allows ablation
of 3.5–4 cm spherical tumors tissue per cycle at tempera-
ture 70c or higher. Dispersive electrode pads to be applied
to the patient’s thighs and connected to the generator to
close the electric circuit. Patients were discharged the
day following the procedure.
D. MRI examination:
DCE-MRI of the liver: using Resonance Achieva 1.5 T-XR
Class IIa 2010, Philips. Technical considerations for
dynamic MRI of the liver scanning protocol:
 T1 weighted images (T1WIs) gradient echo sequence
(GRE) with and without fat suppression (FS): repetition
time (TR) = 100–200 ms, echo time (TE) 6 8 ms, number
of excitations (NEX) 1–4, matrix 128–256  256 with a
field of view as small as possible, slice thickness 5–
7 mm, slice gap 0–2 mm, flip angle = 90.
 T2 weighted images (T2WIs) fast spin echo sequence
with and without fat suppression (FS): (TR)P
2000 ms, (TE) = 90–120 ms, number of excitations
(NEX) 1–4, matrix 192–256  256 with a field of view
as small as possible, slice thickness 5–7 mm, slice gap
0–2 mm, flip angle = 90.
 Dual echo (in and out phase): (TR) = 99 ms, (TE)
= 4.6 ms in phase and 2.3 ms in out phase WIs, flip
angle = 80.
 (DW-MRI): was performed before the dynamic imaging
using respiratory triggered fat-suppressed single-shot
echoplanar sequence that combined the two diffusion
(motion-probing) gradients before and after the 180
pulse along the three directions of section-select,
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acquisition with an Echo-planar imaging (EPI) readout
was obtained by applying three different b factors of
0, 500, and 1000 s/mm2.
 DCE-MRI: was done after diffusion study to avoid the
effect of contrast agents on ADC value. T1 spoiled gradi-
ent WIs was done after I.V. administration of gadopen-
tetate dimeglumine (Gd-DTPA) (0.1 mmol/kg) using
automatic pump injector at rate of 2 ml/s followed
immediately by 20 ml of sterile 0.9% saline solution
injection {arterial phase (16–20 s), porto-venous phase
(45–60 s) and delayed/equilibrium phase (3–5 min)}.
All patients were imaged in end expiration to limit the
risk of image misregistration. The used MRI pulse
sequences parameters are detailed in Table 1.
 MR images analysis:
Images were sent to the workstation (Phillips Extended
MR Workspace) for further image processing.
 ADC map measurement:-
s ADC maps were generated on the workstation.
s Calculation of the ADC value is an automated
process.
s ROI at the ablation zone.
s ROI at the margins of the ablation zone.
s ROI at segment IV or V of the liver.
 Interpretation of the MR images:
s Signal of the ablation zone at T1, T2, Dual phase and
DW-MRI.
s ADC measurement (mean and ADC ratios) of the
liver parenchyma, ablation zone, at the margins of
the ablation zone and periablation zone.
 DCE-MRI interpretation:
s Pattern of enhancement of ablation zone in arterial,
portal and delayed phases.
s Ill-defined perilesional parenchymal enhancement
may be likely related to post interventional changes:
this is defined as early arterial phase enhancement
beyond the ablated cavity that persists in the
delayed phase.
s Well defined enhancement at the margin of the abla-
tion zone which may be either:Table 1
MRI pu
Sequ
Repe
Echo
Matr
Field
Slice
Inter
Acqu
FlipGranulation tissue: persistent on delayed phase
enhancement.
Nodular or hallow enhancement: that suggest
tumor recurrence/residual.lse sequences parameters.
ences parameters T1WI T2WI In pha
tition time (ms) 100–200 P2000 99
time (ms) 68 ms 90–120 4.6
ix 128–256  256 192–256  256 128–2
of view 380 mm 300 mm 380 m
thickness 5–7 mm 5–7 mm 5–7 m
slice gap 0–2 mm 0–2 mm 0–2 m
isition time 4 min 4 min 4 min
angle 90 90 80 Result of ablation of the tumor: the border of resolved
lesions were smooth but in unresolved lesions were
nodular and irregular.
 Standard of reference:
s It was difficult to obtain pathologic confirmation in
patients who underwent ablation because most of
these patients do not undergo surgery. In addition,
biopsy may result in sampling error as recurrent
lesions are mostly small nodules. So, the standard
of reference was:-
s Resolved lesions are considered if the finding
becomes regressed or disappeared in the follow-up
studies.
s Unresolved lesions are considered if the finding:-se
56  25
m
m
mIncreased in the size of the ablated zone.
Focal area at the margin of the ablated zone that
shows the following:
A. Diffusion hyperintensity (restricted) and (low
ADC value <1.05  103 mm2/s).
B. Early arterial phase enhancement of the ablated
zone which becomes hypointense relative to
the liver parenchyma in the delayed phase.s The general observation period including clinical,
LAB and imaging follow-up within first three months
after the RFA then every 3 months for 1 year, and
every 6 months for 2 years.
Statistical analysis of data:
The collected data were organized, tabulated and statis-
tically analyzed, using statistical package for social science
(SPSS) version 19 (SPSS Inc., Chicago, USA). Mean, standard
deviation, frequency and percentage were used as descrip-
tive. Examining the difference in ADC value in the studied
was performed using unpaired t test. P value less than or
equal to 0.05 was considered significant and <0.01 was
considered highly significant.
Ethical consideration:
Institutional review board (IRB) approval: the protocol
was discussed by the ethical scientific committee for
approving the study and informed consent was obtained
before participation.
Consent procedure:
The Investigator made certain that an appropriate
informed consent process was in place to ensure that
potential research subjects, or their authorized representa-
tives, were fully informed about the nature and objectives
of the clinical study, the potential risks and benefits ofOut phase DWI Dynamic T1WIs
99 1600–2000 140
2.3 70 5
6 128–256  256 144  192 128–256  256
380 mm 300 mm 380 mm
5–7 mm 7–8 mm 5–7 mm
0–2 mm 1 mm 1mm
4min 4 min 15 s
80 180 90
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The Investigator obtained the written, signed informed
consent of each subject, or the subject’s authorized repre-
sentative, prior to performing any study specific proce-
dures on the subject. The Investigator retained the
original signed informed consent form.
Subject confidentiality:
All laboratory specimens, evaluation forms, reports,
video recordings, and other records that leave the site
would not include unique personal data to maintain sub-
ject confidentiality.
3. Results
The study consisted of 50 patients, 40 males and 10
females. Their ages ranged between 45 and 80 years with
the mean age of 60 years. This study included 50 patients,
40 patients (80%) with hepatocellular carcinoma (HCC) and
10 patients (20%) with liver metastases. This shows a more
prevalence of HCC among liver malignancies.
Analysis of ablated lesions characteristics:
Regarding the size, signal intensity, the border of
lesions and periablation tissue changes.
Analysis of diagnostic criteria of DCE-MRI and DW-MRI.
1- DCE-MRI interpretation images:-
The lesions appear mainly hypointense in precontrast
T1 and hyperintense in T2 WIs and in addition show early
arterial enhancement and rapidly washout in porto-venous
and delayed phases. These presentations are suggestive of
residual/recurrent lesions.
2- DW-MRI and ADC map:
Resolved lesions were considered when lost signal on
diffusion images with mild sustained hyperintensity in
ADC map and high ADC value.
Residual/recurrent lesions were identified by a sustain-
ing hyperintensity in the DW-MRI with low signal in ADC
map and combined with low ADC value.
 In our study there are 37 patients (74%) having resolved
lesions while 13 patients (26%) have recurrent/residual
lesions.
 In my study the signal intensity of the ablated zone in
the T1 and T2 WIs, DW-MRI and DCE-MRI, within the
first month after ablation was, 67% of the patients
imaged show heterogeneous high T1 and low T2, 20%
show homogenous high T1 and low T2 signal and
13.3% show homogenous low T1 and high T2 signal,
while in the 4–12 months most of the ablated zones eli-
cit homogenous high T1 and low T2 WIs (e.g. Figs. 1 and
2) (77% of patients imaged within 4–6 months and 85%
of patients imaged within 9–12 months). But the DW-
MRI shows high signal (restricted) and low signal in
ADCmap. The DCE-MRI revealed non enhancing ablated
zones.
 I found the border of resolved lesions was smooth but in
unresolved lesions were nodular in 11 patients out of 13(84.6%) (e.g. Figs. 3 and 4) and irregular in two patients
(15.4%).
 My study demonstrated the signal intensity of the
recurrent/residual lesions in the T1, T2, DW-MRI and
DCE-MRI. I classified the signal intensity of the lesions
into intermediate, high or low signal (relative to the
ablated zone). I found 31% of the recurrent/residual
lesions elicit low T1 and 77% elicit high T2 signal and
but in DW-MRI appears hyperintense (restricted)
whereas necrotic regions appear hypointense and low
signal in ADC map. In DCE-MRI, shown are early arterial
enhancement and rapidly washing out in delayed
images.
 I used b values 0, 500 and 1000 s/mm2 to avoid intra-
voxel perfusion effect which result from low b values
(<50 s/mm2) as well as image degradation from high b
values (>1000 s/mm2). Table 2 shows mean ADC values
of liver parenchyma, ablation zones, residual/recurrent
lesions and periablation tissue changes. Table 3 shows
comparison between mean ADC values of liver parench-
yma, ablated zones, malignant lesions and periablated
tissue changes.
 The measured cutoff value between the completely
ablated lesions and residual/recurrent lesions was
1.05  103 mm2/s. My study showed that ablated
zones can be differentiated from liver parenchyma visu-
ally in the DW-MRI and by means of ADC in all patients.
There is no statistical difference in the mean ADC values
between the ablated zones of the resolved
1.37  103 mm2/s and unresolved lesions
1.39  103 mm2/s (P value 0.7). I also calculated the
ADC ratios between the recurrent/residual lesions and
the liver parenchyma were 0.77. The mean ADC value
within segment VI or V of the liver was
1.18  103 mm2/s denoting parenchymatous liver dis-
ease (in diffuse hepatic diseases, chronic hepatitis and
cirrhosis, lower ADCs are more often found in the liver
parenchyma than in healthy liver).
 I studied the presence of periablated thin and regular
enhancement area surrounding the ablated zone in all
phases of DCE-MRI. These areas had low signal in T1
and high signal in T2 WIs with mild hypointensity in
the DW-MRI which presented in 99% of patients imaged
within the first month after ablation, which persists in
11% of patients imaged at 4–6 months and only in 7%
after 9–12 months. The benign finding (based on the
follow-up study) represented reactive inflammatory
and vascular changes of the liver parenchyma adjacent
to the ablated zones.
4. Discussion
Loco-regional treatment for malignant liver tumours
may lead to stability of tumor size or even an increase in
hepatic tumor size after therapy, a feature that limits the
role of size based criteria for assessing tumor response in
this setting [17]. Conventional MRI is relatively insensitive
to early treatment changes in the setting of malignancy.
Common imaging biomarkers that suggest response to
therapy, such as decreased tumor size, often take weeks
to months to become evident. DWI has been shown to be
Fig. 1. Radiofrequency ablation for HCC at segment 6 after 1 month. (A) and (B). Precontrast axial T1 and T2 WIs the ablated zone appears of high signal in
T1 and low signal in T2 WIs. Dynamic study (C). Arterial, (D) Portal and (E). Delayed phases, the ablation zone revealed no contrast enhancement while the
surrounding parenchyma shows inhomogeneous contrast enhancement during the arterial phase that shows delayed washout in the portal and delayed
phases. (F). DWI and (G). ADC map the ablation zone appears of low signal in the DWIs and high signal in the ADC map (average ADC value = 1.330  103 -
mm2/s). The surrounding ill defined area of low T1 and high signal in T2 WIs appears hyperintense in the DWI and low signal intensity in ADC map,
representing perfusion changes secondary to portal vein thrombosis. Diagnosis: Completely ablated lesion regarding high ADC values.
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the molecular level that result from treatment and, thus,
may be able to predict early tumor response to chemother-
apy or radiotherapy [15]. DWI may have a potential role in
the differentiation of viable tumor from treatment induced
necrosis. ADC quantification technique can be of value for
the evaluation of response to ablative treatments and
locoregional therapies even at an early stage [18]. Adding
DWI to conventional MRI can improve the detection of
viable HCC tumors treated with radiotherapy compared
to conventional MRI alone [19]. The monitoring tumor
response to loco-regional therapy is an increasingly impor-
tant task in oncologic imaging. Early favorable responsegenerally indicates effectiveness of therapy, and may result
in significant survival benefit. Early identification of treat-
ment failure is also critical in patient management, since a
repeat treatment cycle can be performed if liver function is
maintained, before disease progression occurs [14]. The
diagnostic management of the liver after RFA remains a
challenging issue that is related to difficulties in accurately
differentiating residual or recurrent vital tumor from non
tumoral tissue changes following thermal therapy. DWI is
increasingly applied in the evaluation of treatment effec-
tiveness in the oncologic patient [20]. The DWI, a func-
tional MRI technique, detects MR signal changes in
tissues due to water proton motion that varies based upon
Fig. 2. Radiofrequency ablation for solitary hepatic metastases from cancer colon in segment 6 after 12 months. (A). Precontrast axial T1WI the ablated zone
shows high signal intensity with interior low signal intensity. (B) Dynamic study late arterial phase shows faint marginal enhancement of the ablated area.
(C) DWI, the ablated zone shows interior low signal and marginal high signal intensity. (D) ADC map, the ablated zone appears isointense to liver
parenchyma (average ADC value = 1.380  103 mm2/s). Diagnosis: Completely ablated lesion regarding high ADC value.
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branes of viable tumor cells restrict water diffusion;
whereas necrotic tumor cells with disrupted cell mem-
branes exhibit increased water diffusion. This mobility of
water is quantified by a constant known as the ADC [21].
The DWI can provide qualitative and quantitative informa-
tion about molecular tissue characteristics and may offer
additional diagnostic information in the follow-up MRI
after hepatic RFA [22].
My study is in agreement with other studies [23,24],
and DWI was performed before the dynamic study to avoid
the effect of contrast agents on ADC values. Chiu et al. [25]
considered that intravenous contrast agent could affect
DWI in two ways. For example, the ADC may decrease
slightly because the contrast agent decreases the intravas-
cular signal intensity. This might lead to suppression of the
perfusion effect on the calculated ADC. Second, the T2
shortening effect of contrast agent may decrease the signal
intensity of the DWI images at b = 0 and b = 500 s/mm2.
In the current study DWI was done by using respiratory
triggered fat suppressed single shot echoplanar sequence.
Kandpal et al. [26] report that high concordance of results
of ADC evaluation used both breath hold and respiratory
triggering examination techniques considering the fact
that respiratory triggering imaging requires longer acquisi-
tion time (approximately several minutes in respiratory
triggering imaging compared to 25 s in breath-hold
sequences).Kim et al. [27] mentioned that the dynamic contrast
enhanced MRI can assess the change in tumor vascularity
and perfusion local ablation therapy.
In my study the signal intensity of the ablated zone in
the T1 and T2 WIs, DW-MRI and DCE-MRI, within the first
month after ablation was, 67% of the patients imaged show
heterogeneous high T1 and low T2, 20% show homogenous
high T1 and low T2 signal and 13.3% show homogenous
low T1 and high T2 signal, while in the 4–12 months most
of the ablated zones elicit homogenous high T1 and low T2
WIs (77% of patients imaged within 4–6 months and 85% of
patients imaged within 9–12 months). But the DW-MRI
shows high signal (restricted) and low signal in ADC
map. The DCE-MRI revealed non enhancing ablated zones.
Kierans et al. [6] performed a study over 203 ablated
lesions for which MRI was acquired <4, 4–9, and >9 months
after RFA. They found that 87.8% of the ablation zones
imaged within the first 4 months after ablation show high
T1 signal with persistence of the high signal in about 84.1%
in patients imaged >9 months after ablation. Braga et al.
[28] stated that the treated lesion exhibits increased signal
on T1 and decreased signal intensity on T2 WIs. The
heterogeneous appearance of the ablation zone reflecting
the different post treatment tissue changes that can be
found after RFA is mainly due to coagulative necrosis, hem-
orrhagic products, and dehydration. In the study per-
formed by Batra and Tripathi [29], sterile liquefactive
necrosis and intracavitary microhemorrhage are accepted
Fig. 3. Radiofrequency ablation for HCC at segment 7 after 3 months. (A). Precontrast coronal T1WI, the ablated zone shows peripheral high signal intensity.
(B) Dynamic study late arterial phase the ablated zone shows faint enhancement with faint nodular marginal enhancement. (C). Portal phase the ablated
zone shows early washout. (D). DWI the lesion shows heterogeneous bright signal (restricted diffusion). (E) Corresponding ADC map, the lesion shows
heterogeneous low signal (average ADC value = 1  103 mm2/s). Diagnosis: Incomplete ablated lesion with eccentric residual area revealed low ADC value.
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tic necrosis of malignant lesions. Sainani et al. [30]
reported in dynamic study the ablation zone is well demar-
cated and no enhancement suggests a lack of viable tumor
and indicates treatment was adequate.
I reported the border of resolved lesions was smooth
but in unresolved lesions whereby nodular in 11 patientsout of 13 (84.6%) and irregular in two patients (15.4%). This
agrees with another study [31] which reported that the
77.5% of the recurrent lesions show small nodules at the
ablation zone margins and 22.5% of the lesions show thick
irregular rim at the ablation zone margins. Also Minami
et al. [32] and Koda et al. [33] found that the recurrent or
residual rate tends to be lower in HCC patients with an
Fig. 4. Radiofrequency ablation for metastatic lesion at segment 8 after 6 months. (A). Precontrast Axial T1 WIs the ablated zone revealed high signal at the
lateral aspect with a small low signal area at its medial portion. (B). Axial T2WIs revealed low signal lateral aspect with high signal of the medial portion. (C)
Dynamic study arterial phase shows enhancement of the medial residual portion of the ablated zone. (D) DWIs shows restricted diffusion of the medial
nodular portion. (E) Corresponding ADCmap, the lesion appears low signal (average ADC value = 1.111  103 mm2/s). Diagnosis: Incomplete ablated lesion
with eccentric nodular residual area revealed low ADC value.
Table 2
Mean ADC values of liver parenchyma, ablated zones, residual/recurrent
lesions and periablated tissue changes.
Category No. Mean ADC (mm2/s) SD
Liver parenchyma 50 1.18  103 0.07
Ablated zones 50 1.38  103 0.19
Residual/recurrent lesions 13 0.91  103 0.09
Periablated tissue changes 30 1.29  103 0.12
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recurrent/residual mainly occurs in the periphery of the
ablation zone which is often not completely included inthe ROI, being drawn along the macroscopically visible
contours of the ablation zone; thus, it is very important
to analyze the periphery of the ablation zone separately.
This is in accordance with our study in which we used
ROI at peripheral and center of ablation lesions.
My study demonstrated that the signal intensity of the
recurrent/residual lesions in the T1, T2, DW-MRI and DCE-
MRI. I classified the signal intensity of the lesions into
intermediate, high or low signal (relative to the ablated
zone). I found 31% of the recurrent/residual lesions elicit
low T1 and 77% eliciting high T2 signal and but in DW-
MRI appears hyperintense (restricted) whereas necrotic
Table 3
Comparison between Mean ADC values of liver parenchyma, ablated zones, malignant lesions and periablated tissue changes.
Ablated zones in all patients (N = 50) SD Liver parenchyma in all patients (N = 50) SD ADC ratio P value
1.38  103 mm2/s ±0.17 1.18  103 mm2/s ±0.06 1.15 0.0001
Residual/recurrent lesions (N = 13) Ablated zones in all patients (N = 50) ADC ratio P value
0.91  103 mm2/s ±0.08 1.38  103 mm2/s ±0.17 0.66 0.0001
Residual/recurrent lesions (N = 13) Liver parenchyma in all patients (N = 50) ADC ratio P value
0.91  103 mm2/s ±0.08 1.18  103 mm2/s ±0.06 0.77 0.0001
Ablated zones in the resolved lesion (N = 37) Ablated zones in the residual/recurrent lesions (N = 13) P value
1.37  103 mm2/s ±0.19 1.39  103 mm2/s ±0.08 0.7
Residual/recurrent lesions (N = 13) Periablated tissue changes (N = 30) ADC ratio P value
0.91  103 mm2/s ±0.08 1.29  103 mm2/s ±0.11 0.70 0.0001
P value < 0.001 = very highly significant.
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DCE-MRI, shown are early arterial enhancement and
rapidly washing out in delayed images. Sainani et al. [30]
found that the recurrence lesions appear isointense to
hypointense on T1WIs, and are isointense to moderately
hyperintense on T2 WIs. In dynamic study arterial
enhancement is seen on T1WIs and washout on delayed
images. Schraml et al. [34] mentioned that viable tumor
regions appear hyperintense on DWIs, whereas necrotic
regions appear hypointense.
My study had b values 0, 500 and 1000 s/mm2 to avoid
intravoxel perfusion effect which results from low b values
(<50 s/mm2) as well as image degradation from high b val-
ues (>1000 s/mm2). Jiang et al. [35] stated that the signal
intensity on DWI is a mixture of diffusion and perfusion.
On DWI obtained with a low b-value, perfusion effects usu-
ally cause larger signal attenuation than diffusion effects.
Also they stated that the image quality diminished greatly
with increasing b value especially on b 2000 DWI.
Taouli et al. [36] found that ADC values were affected by
intravoxel perfusion and were usually overestimated when
a low b factor was applied. Thus, they avoided using low b
factors in their study on liver. Although high b factors of up
to 1000 s/mm2 were required to determine virtually true
ADCs, they used a middle-range b factor of 500 s/mm2,
because liver contours were obscured due to weak signals
in the liver when high b factors were used, which ham-
pered radiologist interpretation in the clinical setting.
I found that the mean ADC value of the liver parench-
yma was 1.18  103 mm2/s, ablated zone in all patients
was 1.38  10–3 mm2/s (P value 0.0001), recurrent/resid-
ual lesion was 0.91  103 mm2/s for ablated zones in the
resolved lesions (1.37  103 mm2/s) while for ablated
zones in the residual/recurrent lesions was
1.39  103 mm2/s (P value 0.7), for periablated tissue
changes (1.29  103 mm2/s). My results agreed with
those of Schraml et al. [34] who studied 148 consecutive
follow-up MRI of 54 patients after RFA of malignant focal
lesions. They found that mean ADC value of the liver par-
enchyma was 1.06 ± 0.21  103 mm2/s while for the
ablated zones was 1.19 ± 0.30  103 mm2/s (P value
0.0003). Also they found the mean ADC values of the whole
ablated zones did not significantly differ between the
resolved lesions (1.22 ± 0.30  103 mm2/s) and the unre-
solved lesions (1.19 ± 0.30  103 mm2/s). Again theyfound that the mean ADC value of the recurrent lesions dif-
fers significantly from the mean ADC value of the perile-
sional tissue changes (P value 0.0124). Different studies
by [37–39] worldwide were established to determine the
value of DWI in evaluation of hepatic focal lesions and in
assessment of malignant lesions response after loco-
regional therapy. It was reported that ADC values of benign
hepatic lesions were significantly higher than those of
malignant hepatic tumors, with a P value < 0.05. Szur-
owska et al. [40] stated that quantitative measurements
of diffusion showed that malignant lesions present lower
ADC values than benign ones and surrounding liver
parenchyma.
My study revealed that the ablated zones can be differ-
entiated from liver parenchyma visually in the DWIs and
by means of ADC in all patients. This finding was also sta-
ted by Schraml et al. [34]. I had no statistical difference in
the mean ADC values between the ablated zones of the
resolved 1.37  103 mm2/s and the ablated zones of unre-
solved lesions 1.39  103 mm2/s (P value 0.7). Lu et al. [5]
performed liver MRI study by 3 T for 43 malignant liver
lesions after RFA (at 1 and 6 months). They measured the
ADC value of the whole ablation zones in resolved cases,
at one month was 1.46 ± 0.33  103 mm2/s while at
6 months was 1.52 ± 0.33  103 mm2/s (P value = 0.026).
I also calculated the ADC ratios between the recurrent/
residual lesions and the liver parenchyma was 0.77 ± 0.12.
This agreed with Schraml et al. [34] who found that ADC
ratio between the recurrent/residual lesions and the liver
parenchyma was 0.90 ± 0.21.
In the present study mean ADC value within segment VI
or V of the liver was 1.18  103 mm2/s denoting
parenchymatous liver disease and similar results were also
obtained by Bittencourt et al. [41] who mentioned that
mean ADC value in parenchymatous disease is
1.12  103 mm2/s while in normal liver it is
1.47  103 mm2/s.
The presence of periablated thin and regular enhance-
ment area surrounds the ablation zone in all phases of
dynamic study. These areas had low signal in T1 and high
signal in T2 WIs with mild hypointensity in the DWIs, pre-
sent in 99 % of patients imaged within the first month after
ablation. This persists in 11% of patients imaged at 4–
6 months and only in 7% after 9–12 months. The benign
finding (based on the follow-up study) represents reactive
1204 M.M.S. Mostafa / The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1195–1205inflammatory and vascular changes of the liver parench-
yma adjacent to the ablation zones. This was in line with
results of Kierans et al. [6] who found the perilesional
enhancement in 53.7% of cases imaged <4 months after
RFA, that persists in 25.6% at 4–9 months and only in
12.2% in cases imaged >9 months after RFA. These areas
exhibit mild hyperintensity in DWIs in the 20% of the
patients imaged within the first 6 months after the abla-
tion, persist in 10% in the next follow-up study at 6–
9 months and only in 5% of patients at 9–12 months. Also
Schraml et al. [34] reported perilesional ill-defined area
of diffusion hyperintensity in 22.5% of the patients imaged
within the first 6 months after the ablation, persist in 19.5%
in the next follow-up study at 6–9 months and only in 6.5%
of patients at 9–12 months. Goldberg et al. [42] stated that
benign periablational enhancement surrounding the abla-
tion zone is frequently found to show moderate to intense
peripheral rim like enhancement on the arterial phase of
contrast enhanced MRI which may persist on the delayed
phase. This rim has low signal on T1 and high signal inten-
sity on T2WIs. Histological analysis of the perilesional rim
has revealed that it is initially reactive hyperemia and sub-
sequently fibrosis and a giant cell reaction. Sainani et al.
[30] mentioned that the signal alterations in the periphery
of the ablation zone due to the fact that therapeutically
induced nontumoral tissue changes (e.g., edema, inflam-
mation, fibrosis, and necrosis) usually show low cellularity
and therefore present with less signal in DWI and high
ADC, respectively, and can thereby be distinguished from
tumoral tissue that presents with high signal in DWI and
low ADC value, respectively. Also Kim et al. [27] who in
their studies regarding the DWI and ADC values for
follow-up after ablation, found that ADC could be helpful
for analyzing unclear hyperintense areas adjacent to the
ablation zone. Where differentiation between tumor tissue
and post treatment changes is unambiguous.
Our finding demonstrated that DWI shows viable tumor
regions and suspected areas in the periphery of the ablated
zone could be identified more easily, and analyzed pre-
cisely in conjunction with the conventional T1, T2, and
dynamic contrast enhanced images. Hayashida et al. [43]
demonstrated that in different organs, DWIs have been
used to predict and monitor the effect of several treatment
options and to differentiate between viable and necrotic
tumor tissues. Close and careful follow-up is needed in
patients who underwent treatment by RFA to detect recur-
rence at an early stage. Morani et al. [44] mentioned that
radiologists must interpret DWI in conjunction with other
MRI pulse sequences, especially keeping in mind the pret-
est probability of an abnormality. Overall, the limitation of
the DWI sequence is predominantly lesion characterization
rather than lesion detection.
Limitations of this study include the lack of histological
result. The measurement of the ADC of the entire ablation
zone is not accurate in the detection of the recurrent/resid-
ual lesion within the center of the ablation zone as it could
be masked by the post ablation changes; however, the fact
that most of the recurrence/residual lesions occur at the
periphery of the ablation zone rather that within its center
should be considered. Diffusion weighted imaging may act
as a supplementary sequence to compensate the dynamicMRI in patients who could not hold their breath
adequately.5. Conclusion
DW-MRI and DCE-MRI show viable tumor regions and
suspected areas in the periphery of the ablation zone could
be identified more easily, and analyzed precisely in con-
junction with the conventional T1 and T2WIs. Recognition
of abnormal post RFA imaging findings and differentiation
of abnormal findings from normal post-procedural changes
are important for diagnostic and interventional radiolo-
gists. Early identification of residual or recurrent disease
can facilitate timely retreatment, management, and
follow-up care.Conflict of interest
The authors declare that there are no conflict of
interests.References
[1] Dodd 3rd GD, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y,
et al. Minimally invasive treatment of malignant hepatic tumors: at
the threshold of a major breakthrough. Radiographics 2000;20:9–27.
[2] Ozkavukcu E, Halilog˘lu N, Erden A. Post-treatment MRI findings of
hepatocellular carcinoma. Diagn Interv Radiol 2009;15:111–20.
[3] McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM. Prophylactic
embolization of the cystic artery before radioembolization:
feasibility, safety, and outcomes. Cardiovascular Intervent Radiol
2011;34:786–92.
[4] Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR
imaging after locoregional therapy. Techn Vasc Interventional Radiol
2006;9:125–32.
[5] Lu Tri-Linh, Becce Fabio, Bize Pierre, Denys Alban, Meuli Reto,
Schmidt Sabine. Assessment of liver tumor response by high field
(3 T) MRI after radiofrequency ablation: short and midterm
evolution of diffusion parameters within the ablation zone. Eur J
Radiol 2012;81:944–50.
[6] Kierans AS, Elazzazi M, Braga L, Leonardou 1 Polytimi, Gerber David
A, Burke Charles, et al. Thermoablative treatments for malignant
liver lesions: 10 year experience of MRI appearances of treatment
response. AJR 2010;194:523–9.
[7] Figueiras RG, Padhani AR, Goh VJ, Vilanova JC, González SB, Martín
CV, et al. Novel oncologic drugs: what they do and how they affect
images. Radiographics 2011;31(7):2059–91.
[8] Lee CH, Braga L, de Campos RO, Semelka RC. Hepatic tumor response
evaluation by MRI. NMR Biomed 2011;24(6):721–33.
[9] Bruegel M, Rummeny EJ. Hepatic metastases, use of diffusion
weighted echo-planar imaging. Abdom Imaging 2010;35(4):454–61.
[10] Padhani AR, Koh DM. Diffusion MR imaging for monitoring of
treatment response. Magn Reson Imaging Clin N Am 2011;19
(1):181–209.
[11] Anzidei M, Napoli A, Zaccagna F, Cartocci G, Saba L, Menichini G,
et al. Liver metastases from colorectal cancer treated with
conventional and antiangiogenetic chemotherapy: evaluation with
liver computed tomography perfusion and magnetic resonance
diffusion weighted imaging. J Comput Assist Tomogr 2011;35
(6):690–6.
[12] Heijmen L, Ter Voert EE, Nagtegaal ID, Span P, Bussink J, Punt CJ.
Diffusion weighted MR imaging in liver metastases of colorectal
cancer: reproducibility and biological validation. Eur Radiol 2013;23
(3):748–56.
[13] Wagner M, Doblas S, Daire JL, Paradis V, Haddad N, Leitao H.
Diffusion weighted MR imaging for the regional characterization of
liver tumors. Radiology 2012;264(2):464–72.
[14] Kamel IR, Morgan HR. MRI appearance of treated liver lesions. Proc
Int Soc Mag Reson Med 2011;19.
[15] Kele PG, Van Der Jagt EJ. Diffusion weighted imaging in the liver.
World J Gastroenterol 2010;16(13):1567–76.
M.M.S. Mostafa / The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1195–1205 1205[16] Lu TL, Meuli RA, Marques Vidal PM, Bize P, Denys A, Schmidt S. Inter-
observer and intra-observer variability of the apparent diffusion
coefficient in treated malignant hepatic lesions on a 3.0rT machine:
measurements in the whole lesion versus in the area with the most
restricted diffusion. J Magn Reson Imaging 2010;32(3):647–53.
[17] Gonzalez Guindalini Fernanda D, Botelho Marcos PF, Harmath Carla
B, Sandrasegaran Kumaresan, Miller Frank H, Salem Riad, et al.
Assessment of liver tumor response to therapy: role of quantitative
imaging. Radiographics 2013;33:1781–800.
[18] De Robertis Riccardo, Martini Paolo Tinazzi, Demozzi Emanuele,
Puntel Gino, Ortolani Silvia, Cingarlini Sara, et al. Prognostication
and response assessment in liver and pancreatic tumors: the new
imaging. World J Gastroenterol 2015;21(22):6794–808.
[19] Park HJ, Kim SH, Jang KM, Lim S, Kang TW, Park HC, et al. Added
value of diffusion weighted MRI for evaluating viable tumor of
hepatocellular carcinomas treated with radiotherapy in patients
with chronic liver disease. AJR 2014;202(1):92–101.
[20] Koh DM, Collins DJ. Diffusion-weighted MRI in the body:
applications and challenges in oncology. AJR Am J Roentgenol
2007;188:1622–35.
[21] Chung Johnathan C, Naik Neel K, Lewandowski Robert J, Deng Jie,
Mulcahy Mary F, Kulik Laura M, et al. Diffusion weighted magnetic
resonance imaging to predict response of hepatocellular carcinoma
to chemoembolization. World J Gastroenterol. 2010;16(25):3161–7.
[22] Vandecaveye V, De Keyzer F, Nuyts S, Deraedt K, Dirix P, Hamaekers
P, et al. Detection of head and neck squamous cell carcinoma with
diffusion weighted MRI after (chemo) radiotherapy: correlation
between radiologic and histopathological findings. Int J Radiat Oncol
Biol Phys 2007;67(4):960–71.
[23] Yu JS, Kim JH, Chung JJ, Kim KW. Added Value of diffusion weighted
imaging in the MRI assessment of perilesional tumor recurrence
after chemoembolization of hepatocellular carcinomas. J Magn
Reson Imaging 2009;30(1):153–60.
[24] Goshima S, Kanematsu M, Kondo H, Yokoyama R, Kajita K, Tsuge Y,
et al. Diffusion weighted imaging of the liver: optimizing b value for
the detection and characterization of benign and malignant hepatic
lesions. J Magn Reson Imaging 2008;28(3):691–7.
[25] Chiu FY, Jao JC, Chen CY, Liu GC, Jaw TS, Chiou YY, et al. Effect of
intravenous gadolinium DTPA on diffusion weighted magnetic
resonance images for evaluation of focal hepatic lesions. J Comput
Assist Tomogr 2005;29(2):176–80.
[26] Kandpal H, Sharma R, Madhusudhan KS, Kapoor KS. Respiratory
triggered versus breath hold diffusion weighted MRI of liver lesions:
comparison of image quality and apparent diffusion coefficient
values. AJR 2009;192(4):915–22.
[27] Kim KW, Lee JM, Choi BI. Assessment of the treatment response of
HCC. Abdom Imaging 2011;36:300–14.
[28] Braga L, Armao D, Azzazi ME, Semelka RC. Liver. In: Semelka RC,
editor. Abdominal-pelvic MRI. Hoboken (NJ): Wiley-Blackwell;
2010. p. 45–454.
[29] Batra, Tripathi RP. Atypical diffusion-weighted magnetic resonance
findings in glioblastoma multiforme. Australas Radiol 2004;48
(3):388–91.
[30] Sainani Nisha I, Gervais Debra A, Mueller Peter R, Arellano Ronald S.
Imaging after percutaneous radiofrequency ablation of hepatic
tumors: Part 2, abnormal findings. AJR 2013:194–204.[31] Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, et al.
Hepatic tumors treated with percutaneous radio-frequency
ablation: CT and MR imaging follow up. Radiology
2002;223:255–62.
[32] Minami Y, Nishida N, Kudo M. Therapeutic response assessment of
RFA for HCC: contrast-enhanced US, CT and MRI. World J
Gastroenterol 2014;20(15):4160–6.
[33] Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al.
Assessment of ablative margin by unenhanced magnetic resonance
imaging after radiofrequency ablation for hepatocellular carcinoma.
Eur J Radiol 2012;81(10):2730–6.
[34] Schraml C, Schwenzer N, Clasen S, Rempp HJ, Martirosian P, Claussen
CD, et al. Navigator respiratory triggered diffusion weighted imaging
in the follow up after hepatic radiofrequency ablation initial results.
J Magn Reson Imaging 2009;29:1308–16.
[35] Jiang Zhao-Xia, Peng Wei-Jun, Li Wen-Tao, Tang Feng, Liu Shi-Yuan,
Qu Xu-Dong, et al. Effect of b value on monitoring therapeutic
response by diffusion weighted imaging. World J Gastroenterol
2008;14(38):5893–9.
[36] Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of
liver diffusion isotropy and characterization of focal hepatic lesions
with two single-shot echoplanar MR imaging sequences:
prospective study in 66 patients. Radiology 2003;226:71–8.
[37] Miller FH, Hammond N, Siddiqi AJ, Shroff S, Khatri G, Wang Y, et al.
Utility of diffusion weighted MRI in distinguishing benign and
malignant hepatic lesions. J Magn Reson Imaging 2010;32
(1):138–47.
[38] Vergara ML, Fernández M, Pereira R. Diffusion weighted MRI
characterization of solid liver lesions. Revista Chilena De
Radiología 2010;16(1):510.
[39] Onur MR, Cicekci M, Kayali A, Poyraz AK, Kocakoc E. The role of ADC
measurement in differential diagnosis of focal hepatic lesions. Eur J
Radiol 2012;81(3):171–6.
[40] Szurowska E, Nowicki TK, Swieszewska EI, Zadrozny Dariusz,
Markiet Karolina, Studniarek Michal. Predictive value of apparent
diffusion coefficient in evaluation of colorectal carcinoma hepatic
metastases response to radiofrequency ablation. J Magn Reson
Imaging 2013;38(5):991–1297.
[41] Bittencourt LK, Matos C, Coutinho AC. Diffusion-weighted magnetic
resonance imaging in the upper abdomen: technical issues and
clinical applications. Magn Reson Imaging Clin N Am
2011;19:111–31.
[42] Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd 3rd GD,
Dupuy DE, et al. Image guided tumor ablation: standardization of
terminology and reporting criteria. J Vasc Interv Radiol 2009;20(7):
S377–90.
[43] Hayashida Y, Yakushiji T, Awai K, Katahira K, Nakayama Y,
Shimomura O, et al. Monitoring therapeutic responses of primary
bone tumors by diffusion weighted image: initial results. Eur Radiol
2006;16(12):2637–43.
[44] Morani Ajaykumar C, Elsayes Khaled M, Liu Peter S, Weadock
William J, Szklaruk Janio, Dillman Jonathan Russell, et al. Abdominal
applications of diffusion weighted magnetic resonance imaging:
where do we stand. World J Radiol 2013;5(3):68–80.
